AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
08/07/26	€0.7400	-1.99%	270,840
07/07/26	€0.7550	-0.66%	171,340
06/07/26	€0.7600	-1.68%	216,989
03/07/26	€0.7730	+0.78%	308,587
02/07/26	€0.7670	-1.67%	745,893

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 19:55:00 08/07/2026 +04			5-day change	1st Jan Change
0.7400 ^EUR	-1.99%		-5.13%	-51.82%

07-01	AB Science, successful private placement
07-01	AB Science S.A. announced that it has received ?2.294 million in funding	CI

Market Cap	59.21M 67.51M 54.66M 50.52M 95.75M 6.46B 97.66M 657M 255M 3.16B 254M 248M 10.98B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	59.21M 67.51M 54.66M 50.52M 95.75M 6.46B 97.66M 657M 255M 3.16B 254M 248M 10.98B	EV / Sales 2026 *	49.3x	EV / Sales 2027 *	45.5x
Free-Float	72.29%	Yield 2026 *	-	Yield 2027 *	-

07-01	AB Science, successful private placement
07-01	AB Science S.A. announced that it has received ?2.294 million in funding	CI
06-29	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
06-29	AB Science completes Step 3 of a Phase 1 study
06-18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
06-18	AB Science Secures New U.S. Patent for Masitinib
06-17	AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042	CI
06-10	AB Science presents new data on Masitinib
05-18	AB Science S.A. announced that it has received $2.989368 million in funding	CI
05-13	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-04	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
04-29	Airbus, Pernod Ricard, Sopra Steria, TotalEnergies, TP... stocks to watch today in Paris
04-29	AB Science announces successful capital increase

07-08	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU
07-01	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	AQ
06-17	AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042	GL

AB Science Stock

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

07-08	Stéphane Ledermann prend les rênes d'AB Science en tant que PDG
07-07	Ab Science : Nomination de Stéphane LEDERMANN en qualité de Président Directeur Général
07-01	AB Science : Résultats de l'Assemblée Générale Mixte du 30 juin 2026
07-01	Bourse : Schneider se renforce dans l'IA, Air Liquide investit pour SK Hynix, Nike déçoit
07-01	AB Science, succès d'un placement privé

1 day	-1.99%
1 week	-5.13%
Current month	-16.38%
1 month	-15.91%
3 months	-37.92%
6 months	-49.59%
Current year	-51.82%

1 week	0.72	0.78
1 month	0.72	0.94
Current year	0.72	1.61
1 year	0.72	1.73
3 years	0.72	4.46
5 years	0.72	16.68
10 years	0.72	21.75

Manager	Title	Age	Since
Alain Moussy CEO	Chief Executive Officer	-	11/07/2001
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
05-20	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
09/02/21	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
02/02/21	Jean-Pierre Kinet	Sell	Founder	12,904	0.0280%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-1.99%	-5.13%	-48.11%	-81.17%	69.03M
MERCK & CO., INC.	-2.23%	+0.49%	+54.84%	+15.59%	318B
MERCK KGAA	-1.83%	-3.70%	+24.69%	-5.02%	70.43B
HALOZYME THERAPEUTICS, INC.	-1.47%	+4.36%	+44.03%	+119.47%	9.68B
KYOWA KIRIN CO., LTD.	-0.30%	+1.54%	+6.56%	+2.69%	8.78B
SK BIOPHARMACEUTICALS CO., LTD.	-3.30%	-5.31%	-11.43%	+8.89%	4.39B
BETTA PHARMACEUTICALS CO., LTD.	-4.32%	-8.76%	+10.18%	+19.21%	4.01B
YUHAN CORPORATION	-1.71%	-1.99%	-35.06%	+27.96%	3.46B
SUPERNUS PHARMACEUTICALS, INC.	+5.21%	+6.39%	+57.18%	+70.18%	2.78B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-3.49%	-7.20%	+9.26%	-24.63%	2.16B
Average	-1.24%	-1.33%	+11.21%	+15.32%	42.4B
Weighted average by Cap.	+0.18%	-0.33%	+46.51%	+14.47%

	2026 *	2027 *
Net sales	1.2M 1.37M 1.11M 1.02M 1.94M 131M 1.98M 13.32M 5.17M 64.11M 5.14M 5.03M 223M	1.3M 1.48M 1.2M 1.11M 2.1M 142M 2.14M 14.43M 5.61M 69.45M 5.57M 5.44M 241M
Net income	-	-
Net Debt	-	-